Biomedical subjects
Publications and source records attributed to V Mutt.
Explore the source record for details and available documents.
The isolation of a novel biologically active peptide, designated galanin, is described. The peptide was discovered by the detection of its C-terminal amide structure in porcine intestinal extract using a chemical method. It was found that galanin consists of 29 amino acids and the complete amino acid sequence is: Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His -Arg-Ser -Phe-His-Asp-Lys-Tyr-Gly-Leu-Ala-NH2. Galanin was found to contract smooth muscle preparations from the rat and to cause a mild and sustained hyperglycemia in dog.
Porcine intestinal gastrin-releasing peptide (GRP) has been demonstrated to be structurally identical to the previously characterized gastric GRP. Ion-exchange and high-performance liquid chromatography of porcine intestinal extracts have identified two variant GRP forms. Studies on one of these variant forms suggest that a beta-aspartyl shift has occurred in the Asn-His structure of GRP; such a modification in an Asn-His structure occurring in a natural peptide or protein has not been previously reported. This variant GRP, although retaining bioactivity, appears to have reduced potency in elevating canine plasma gastrin levels.
Weak to strong gastrin releasing peptide--bombesin (GRP-Bn)-like immunoreactivity was found in fine varicose nerve terminal systems of low to high densities in several parts of the CNS. The highest densities of strongly immunoreactive terminals were found in the marginal layer and in the substantia gelatinosa of the spinal cord, and in parts of the nuc. tractus spinalis nervi trigemini. Morphometrical analysis in the spinal cord demonstrates that GRP-BN-like-immunoreactive and substance P (SP), but not somatostatin (SS)-immunoreactive nerve terminals strikingly codistribute. Coexistence of SP and GRP-BN-like immunoreactivities was demonstrated in trigeminal and spinal ganglion nerve cells. Thus, GRP-BN-like immunoreactivity may coexist with SP in certain SP-immunoreactive nerve terminal systems.
Explore the source record for details and available documents.
The isolation of a brain peptide identical to the intestinal peptide PHI (peptide HI) is described. The peptide was isolated from porcine brain extract using a chemical assay method based on its C-terminal isoleucine amide structure. The complete amino acid sequence of the peptide was found to be: His-Ala-Asp-Gly-Val-Phe-Thr-Ser-Asp-Phe-Ser-Arg-Leu-Leu-Gly-Gln-Leu-Ser-Ala- Lys-Lys-Tyr-Leu-Glu-Ser-Leu-Ile-NH2. This sequence is identical to the intestinal peptide thus demonstrating PHI to be a brain-gut peptide. The role of PHI in the central nervous system as a neurotransmitter or neuromodulator is discussed.
Explore the source record for details and available documents.
A new polypeptide hormone candidate regulating vascular smooth muscle function was extracted from porcine atrial tissue. The purification steps were followed by a bioassay. The hormonally active substance has been analyzed and found to be a small polypeptide exhibiting a molecular weight of about 7500 and is named "cardiodilatin" (CDD). Further chemical data on this new hormone will be published elsewhere. A partial amino acid sequence of cardiodilatin is offered and shows that among the well known hormones or neuropeptides, none exhibit a homologue partial sequence.
By using the indirect immunofluorescence technique, one and the same neuron in the parvocellular part of the paraventricular nucleus has been shown to stain with antisera against three different peptides: PHI (PHI-27), corticotropin-releasing factor (CRF), and enkephalin. This could explain the well-known parallel increase in plasma prolactin, corticotropin, and growth hormone levels--for example, under certain types of stress--as being due to a concomitant release of PHI-like, CRF-like, and enkephalin-like peptides from the same nerve endings in the median eminence. A hypothetical mechanism for the co-ordinated release of these three anterior pituitary hormones is discussed.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The present study demonstrates that PHI, a peptide belonging to the glucagon-secretin group and thus structurally similar to VIP, can release prolactin from dispersed rat anterior pituitary cells and also causes release of prolactin from hemipituitaries. PHI-like immunoreactivity has previously been demonstrated in a hypothalamic system with nerve endings in the median eminence, and, taken together, these findings suggest that PHI may represent a physiologic prolactin-releasing factor.
Substance P (SP) (10(-8) M) can rapidly reduce the affinity and increase the density of 3H-5-HT binding sites in spinal cord membranes. CCK-8 and CCK-4 (10(-8) M) can rapidly and differentially change the characteristics of 3H-spiperone striatal binding sites linked to DA receptors of the D2 type. CCK-4 increase and CCK-8 reduce the number of striatal binding sites for 3H-spiperone, indicating for the first time separate CCK-4 binding sites. CCK-4 (10(-8) M) but not CCK-8 (10(-8) M) can rapidly reduce the affinity and increase the number of the 3H-spiperone binding sites linked to 5-HT receptors of the dorsal cerebral cortex of rats. CCK-8 (10(-8) M) only produces a trend for a small increase in the Bmax values of these receptors. These results again imply the existence of separate CCK-4 binding sites in this case in the cerebral cortex. Glutamate (10(-6) M), but not N-methyl-D-aspartate (10(-6) M) can rapidly change the characteristics of the 3H-N-propylnorapomorphine (3H-NPA) binding sites in striatal membranes of rats. Glutamate (10(-6) M) increases the density and especially reduces the affinity of the 3H-NPA binding sites, which label D2 and D3 types of DA receptors. Taken together the present findings give evidence that neuropeptide receptors and glutamate receptors can in vitro rapidly modulate the characteristics of different types of DA and 5-HT receptors by way of receptor--receptor interactions at the comodulate level or at the local circuit level. It is hypothesized that these receptor--receptor interactions are of importance for the encoding of short-term memory.
The inhibitory effect of peptide YY on contractile activity in the innervated main stomach and the vagally denervated fundic pouch in conscious Heidenhain pouch dogs was investigated. Peptide YY was given in i.v. bolus injections of doses between 12.5 and 100 pmol/kg body wt. During the digestive state, 2-3 h after feeding, peptide YY was found to have no effect on contractile activity in either the innervated or the vagally denervated stomach. In the interdigestive state, it was found that peptide YY inhibited the interdigestive migrating contractions in the innervated main stomach dose-dependently for 1.2 +/- 0.1 to 5.8 +/- 0.3 min, but did not affect pouch contractions at all. This peptide, however, did not influence the cycle of the interdigestive migrating contractions. Pentagastrin, on the other hand, suppressed the interdigestive migrating contractions in the innervated main stomach when the bolus doses were greater than 300 pmol/kg body wt, but did not inhibit pouch contractions completely with this dose. Atropine (0.05 mg/kg body wt) suppressed contractions in both the main stomach and the vagally denervated pouch. Peptide YY inhibits the interdigestive migrating contractions in the stomach through the extrinsic nerves.
A 37 amino acid-peptide has been isolated from porcine jejuno-ileum on the basis of its glucagon-like activity in liver (interaction with glucagon-binding sites and activation of adenylate cyclase) using gel filtration, ion-exchange and high-performance liquid chromatography. Depending on the criteria chosen, this peptide is referred to as either 'bioactive enteroglucagon' (activity in liver), 'oxyntomodulin' (specific action in gastric oxyntic glands) or 'glucagon-37' (chemical structure).
A peptide isolated from porcine gut according to its glucagon-like activity in liver (bioactive enteroglucagon) has been characterized immunologically, biologically and chemically: its potency relative to pancreatic glucagon in interacting with an antiglucagon antibody, hepatic glucagon-binding sites and hepatic adenylate cyclase was approximately 100%, 20% and 10%, respectively. In contrast, it is approximately 20-times more potent than glucagon in oxyntic glands, justifying the term 'oxyntomodulin'. Chemically, it consists in the 29 amino acid-peptide glucagon elongated at its C-terminal end by the octapeptide Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala; accordingly, it is called 'glucagon-37'.